- Neos Therapeutics (NASDAQ:NEOS) has entered into a confidential settlement and licensing agreement with Teva Pharmaceuticals (TEVA) to resolve all ongoing litigation involving Neos' patents protecting its Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets and Teva's ANDA filed with the FDA to market a generic version of that product.
- Under the settlement and license agreement, Neos has granted Teva the right to manufacture and market its generic version of Cotempla XR-ODT under the Teva ANDA beginning on July 1, 2026, or earlier.
- The settlement and licensing agreement is confidential and the agreement is subject to submission to the Federal Trade Commission and the U.S. Department of Justice.
- TEVA shares are up 2% premarket.